Hepatic copper in primary biliary cirrhosis: biliary excretion and response to penicillamine treatment. 1981

M P Salaspuro, and P Pikkarainen, and P Sipponen, and E Vuori, and T A Miettinen

Excessive hepatic copper accumulation occurs in long-lasting cholestatic liver disorders especially in primary biliary cirrhosis. As in Wilson's disease, penicillamine has recently been introduced for the treatment of primary biliary cirrhosis. In Wilson's disease there is decreased biliary excretion of copper. The present study shows that as compared with controls the biliary excretion of copper is not decreased in primary biliary cirrhosis; instead it may be increased in some patients. However, when compared with high hepatic copper concentration biliary copper excretion was low. In contrast with copper, biliary secretion of bile acids was decreased in eight of the 17 patients. Treatment with oral penicillamine (600 mg/day) for one year resulted in a significant decrease of hepatic copper concentration, but had no consistent effect on the biliary excretion of copper or on the amount of histologically stainable orcein-positive copper-binding protein. The results suggest that excessive hepatic copper accumulation in primary biliary cirrhosis may not be primarily caused by a decreased biliary excretion, or that a new equilibrium is achieved in advanced primary biliary cirrhosis. D-penicillamine appears to improve significantly the biliary excretion of bile acids.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008105 Liver Cirrhosis, Biliary FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes. Biliary Cirrhosis,Biliary Cirrhosis, Primary,Biliary Cirrhosis, Secondary,Cholangitis, Chronic Nonsuppurative Destructive,Liver Cirrhosis, Obstructive,Primary Biliary Cholangitis,Biliary Cirrhosis, Primary, 1,Primary Biliary Cirrhosis,Secondary Biliary Cholangitis,Secondary Biliary Cirrhosis,Biliary Cholangitides, Primary,Biliary Cholangitis, Primary,Biliary Cholangitis, Secondary,Cholangitides, Primary Biliary,Cholangitis, Primary Biliary,Cholangitis, Secondary Biliary,Cirrhosis, Biliary,Cirrhosis, Secondary Biliary,Liver Cirrhoses, Biliary,Obstructive Liver Cirrhosis,Primary Biliary Cholangitides,Secondary Biliary Cholangitides
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010396 Penicillamine 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. Dimethylcysteine,Mercaptovaline,beta,beta-Dimethylcysteine,Copper Penicillaminate,Cuprenil,Cuprimine,D-3-Mercaptovaline,D-Penicillamine,Metalcaptase,D 3 Mercaptovaline,D Penicillamine,Penicillaminate, Copper,beta,beta Dimethylcysteine
D003300 Copper A heavy metal trace element with the atomic symbol Cu, atomic number 29, and atomic weight 63.55. Copper-63,Copper 63
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M P Salaspuro, and P Pikkarainen, and P Sipponen, and E Vuori, and T A Miettinen
January 1979, The Yale journal of biology and medicine,
M P Salaspuro, and P Pikkarainen, and P Sipponen, and E Vuori, and T A Miettinen
November 1978, Lancet (London, England),
M P Salaspuro, and P Pikkarainen, and P Sipponen, and E Vuori, and T A Miettinen
February 1981, Clinical science (London, England : 1979),
M P Salaspuro, and P Pikkarainen, and P Sipponen, and E Vuori, and T A Miettinen
May 1977, Lancet (London, England),
M P Salaspuro, and P Pikkarainen, and P Sipponen, and E Vuori, and T A Miettinen
June 1981, Lancet (London, England),
M P Salaspuro, and P Pikkarainen, and P Sipponen, and E Vuori, and T A Miettinen
March 1993, Nagoya journal of medical science,
M P Salaspuro, and P Pikkarainen, and P Sipponen, and E Vuori, and T A Miettinen
February 1985, Gut,
M P Salaspuro, and P Pikkarainen, and P Sipponen, and E Vuori, and T A Miettinen
October 2004, The Cochrane database of systematic reviews,
M P Salaspuro, and P Pikkarainen, and P Sipponen, and E Vuori, and T A Miettinen
November 1982, The British journal of dermatology,
M P Salaspuro, and P Pikkarainen, and P Sipponen, and E Vuori, and T A Miettinen
September 1981, Lancet (London, England),
Copied contents to your clipboard!